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Maple syrup urine disease (MSUD) is a rare, autosomal recessive disorder of branched-chain amino acidmetabolism.
We noted that a large proportion (10 of 34) of families with MSUD that were followed in our clinic were of
Ashkenazi Jewish (AJ) descent, leading us to search for a common mutation within this group. On the basis of
genotyping data suggestive of a conserved haplotype at tightly linked markers on chromosome 6q14, the BCKDHB
gene encoding the E1b subunit was sequenced. Three novel mutations were identified in seven unrelated AJ patients
with MSUD. The locations of the affected residues in the crystal structure of the E1b subunit suggested possible
mechanisms for the deleterious effects of these mutations. Large-scale population screening of AJ individuals for
R183P, the mutation present in six of seven patients, revealed that the carrier frequency of the mutant allele was
∼1/113; the patient not carrying R183P had a previously described homozygous mutation in the gene encoding
the E2 subunit. These findings suggested that a limited number of mutations might underlie MSUD in the AJ
population, potentially facilitating prenatal diagnosis and carrier detection of MSUD in this group.
Originally described by Menkes in 1954, as a rapidly
fatal neurodegenerative disease (Menkes et al. 1954),
maple syrup urine disease (MSUD) (types Ia [MIM
248600], Ib [MIM 248611]), and II [MIM 248610]), is
an inborn error of metabolism, resulting from the de-
fective activity of branched-chain a-ketoacid dehydrog-
enase (BCKAD) (Chuang and Shih 2000). The enzymatic
defect, transmitted in an autosomal recessive manner,
results in an inability to catabolize leucine, isoleucine,
and valine. BCKAD exists as a multienzyme complex
composed of a multimeric core of dihydrolipoyl acyl-
transferase (E2), to which are bound multiple BCKAD
decarboxylase (E1) and dihydrolipoamide dehydroge-
nase (E3) subunits (Pettit et al. 1978). Two regulatory
subunits, BCKAD kinase and BCKAD phosphatase, are
also associated with the E2 core (Damuni et al. 1984;
Reed et al. 1985). The E1 subunit exists as a heterotetra-
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mer composed of two E1a and two E1b subunits. Be-
cause the E3 subunit is shared with the pyruvate and a-
ketoglutarate dehydrogenase complexes, decreased
activity of this component results in deficiencies of all
three enzymes.
Five clinical MSUD phenotypes have been described,
which differ in their presentation and severity. Classic
MSUD, the most common clinical presentation, mani-
fests during the newborn period and can result in severe
neurological complications and death. The less-common
forms are the later-onset intermediate type, an episodic
intermittent type, an intermediate-like thiamin-respon-
sive type, and E3 deficiency with lactic acidosis. Mu-
tations in any of the E1 or E2 components can result in
classic, intermediate, or intermittent MSUD, although
they are more frequent in E1a and E1b than in E2 (Nellis
and Danner 2001). Patients with MSUD can be effec-
tively managed with dietary restriction of the branched-
chain amino acids and maintenance of strict biochemical
control (Snyderman et al. 1964). However, a significant
proportion of treated individuals have impaired intel-
lectual development or neurological complications, par-
ticularly as a result of delayed diagnosis (Kaplan et al.
1991), emphasizing the importance of newborn-screen-
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Table 1
Primers for Exon-Specific PCR amplifications.
GENE AND EXON
PRIMER
(5′r3′)
LENGTH
(bp)Forward Reverse
E1b:
1 TCCAGTTCCGATTGGTCTGT AGCTGGGATGCAAGGATTG 434
2 CCACAATTCAGGCACATATCAG GCATAATATCTTTCTTTGTACCTTGA 222
3 TCCATACAATGGGGATATGACA TGATCGAGATCTATGGTCCATTT 304
4 TCTCATTTGCCACATTAACCTTT GGGTAGCGGCAATACTTGAA 239
5 CCCCGTCTTTCTTTCTGACC TGAATCAAAATGGAAACATCAAA 237
6 AGCCCTTCTTAGCAGCGAGT TTCTACAAGGAAAATATAAATCAACCA 295
7 TGCACAAGTGTCACCTCAGA GCTTCCAAGCACAACGTAGG 205
8 TTTTTGAGGCTAGAACCTTTGT GCCAAAGGTTTCAGGGAAAT 214
9 CATCAGGTTTTTCTTTTCTCTTTCA TCTTCTGGAATTGGCATGTG 175
10 TTGAAGTTAAGCATCCTGACTCTG CGTTAATGTCAGGGGCACAT 400
E2:
2 TTGTGTTCGCTATTTTC CAGCAGTTGTTTTCAGGA 122
ing programs. Despite early diagnosis and adequate care,
episodes of life-threatening metabolic decompensation
occur during periods of stress or infection and are as-
sociated with significant morbidity and mortality (Ri-
viello et al. 1991; Levin et al. 1993; Chuang and Shih
2000).
MSUD has been described in all ethnic groups and
has an estimated worldwide frequency of 1/185,000
(Naylor 1980). However, a founder effect in the Penn-
sylvania Mennonite population has led to an increased
incidence (1/176) in this population (Marshall and
DiGeorge 1981). In our clinic, we noted that a dispro-
portionate percentage (∼30%) of families with MSUD
were of Ashkenazi Jewish (AJ) heritage. Here we report
the carrier frequency of a common AJ mutation, R183P,
and the identification of two novel mutations.
Six unrelated AJ patients with classic MSUD (individ-
uals 2–6 and 9), one patient with intermediate MSUD
(individual 1), and the parents of one classic patient (in-
dividuals 7 and 8) participated in this study. The protocol
was approved by the Mount Sinai School of Medicine
Institutional Review Board, and voluntary informed con-
sent was obtained from all participants. DNA was ex-
tracted either from peripheral blood (PureGene; Gentra)
or from buccal-swab samples (MasterAmp Buccal Kit;
Epicentre Technologies).
Our initial focus was on E2DAT, a 2-bp deletion in
the second exon of the E2 gene, described by Fisher et
al. (1993), in individual 9. This mutation destroys an
AflIII site in the exon, allowing rapid screening of our
AJ patients by amplification of the exon from genomic
DNA (table 1), followed by restriction-enzymedigestion.
The results of the assay demonstrated that the mutation
was found only in individual 9 (not shown). We there-
fore identified polymorphic short tandem-repeat (STR)
markers flanking the genetic loci encoding E1a, E1b,
and E2, to determine whether a conserved haplotype
consistent with a common mutation was present in our
other patients. It is noteworthy that, in order to assess
the BCKDHB locus, we first identified candidate STR
markers that were linkage-mapped to 6p21-p22, the
published cytogenetic localization given in the OMIM
Gene Map (Zneimer et al. 1991). Alignments of gene
(see the GenBank Overview web site ) and marker se-
quences with the genomic sequence data, by use of the
Human Genome Project Working Draft at UCSC, in-
dicated that BCKDHB maps to cytogenetic location
6q14. Radiation-hybrid mapping data from Gene-
Map’99 supported the localization of BCKDHB to
6q14, so markers from this region were used in the
analysis.
STRs tightly linked to the relevant genes were ob-
tained from ResGen. Radiolabeling, amplification, and
electrophoresis were performed by standard methods.
Allele assignments were standardized across gels by use
of CEPH reference individual 1331-2. The genotyping
results were consistent with a disproportionately rep-
resented allele at each of the markers flanking the E1b
locus (fig. 1). In particular, the 7 allele of marker D6S251
was highly overrepresented, being present in all individ-
uals except for individual 9 and accounting for 10 of
12 total alleles. Typing of 50 control AJ chromosomes
gave an estimated 7 allele frequency of ∼8%, confirming
the striking allele-frequency distortion in the patients
with MSUD. Markers flanking the genes encoding E1a
and E2 did not display a pattern consistent with seg-
regation of common alleles (not shown). On the basis
of these suggestive results, mutation analysis of the E1b
exons was performed in individual 4, a homozygote for
the putative three-marker haplotype 1-4-7 at markers
D6S286, D6S460, and D6S251, respectively.
PCR primers were designed to amplify all exons and
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Figure 1 Genomic organization of polymorphic markers tightly
linked to the genes encoding E1a, E1b, and E2 and genotype data for
markers flanking E1b. A, Organization of STR markers used in anal-
ysis of the BCKDHB locus, and their relative spacing, in both physical
and genetic distance. BCKDHB spans ∼240 kb, and the 3′ end lies ∼1
Mb upstream of D6S251. B, Results of genotyping analysis of patients
with intermediate (boxed) or classic (underlined) MSUD. The parents
of individual 5 are denoted by circles. Individual 9 is a patient with
a known mutation (i.e., E2DAT).
proximal intronic sequences (table 1). Amplicons were
column purified by use of the Qiagen PCR Purification
kit and were sequenced bidirectionally on an ABI PRISM
3700 automated sequencer (Applied Biosystems). Traces
were processed by the Factura and Autoassembler soft-
ware packages (Applied Biosystems). A homozygous
missense mutation corresponding to 538GrC in the
cDNA sequence was detected in exon 5 (fig. 2A). Over-
lapping MspI and NlaIV sites in the amplicon were de-
stroyed by the base change, allowing the remaining pa-
tients to be screened with the same primer set as was
used for sequencing (fig. 2B). The mutation was detected
in 10 of 12 chromosomes screened and segregated with
the 7 allele of marker D6S251, unambiguously in eight
instances and presumptively in two instances (fig. 1B).
The 538GrC mutation causes an ArgrPro substi-
tution in E1b, at residue 183 in the mature peptide
(R183P). R183 is conserved between E1b and the ho-
mologous Pseudomonas putida bacterial enzyme and is
located in a b-sheet that contributes to a K ion-binding
pocket close to the interface of the E1a and E1b subunits
(Ævarsson et al. 2000). Hydrogen-bond interactions
made by this residue in the E1 crystal structure were
visualized by use of a SwissPdb-Viewer (fig. 3A) (Guex
and Peitsch 1997). Three parallel b-sheets (d, e, and g)
form extensive interactions in this region of the protein.
Sheet e is central to sheets d and g, and R183 makes
main-chain and side-chain hydrogen-bond interactions
with residues on both adjacent sheets, notably E96 and
E189, residues that were also conserved between mam-
malian and bacterial subunits (fig. 3A). Structural
changes introduced by a Pro substitution would thus be
expected to interfere with a conserved structural motif,
by altering the conformation of the central b-strand and
by disrupting the hydrogen-bond interactions apparently
essential for proper folding of the ion-binding pocket
and/or for subunit interaction. These predictions are
supported by functional data recently described by
Wynn et al. (2001), which demonstrate that the R183P
mutation renders the E1b subunit thermolabile at phys-
iological temperatures. Their studies indicate that the
mutation confers a temperature-dependent folding de-
fect on the E1b subunit, disrupting its ability to complex
with the E1a subunit.
Mutation analysis of compound-heterozygous indi-
viduals 1 and 2 revealed that they contained two ad-
ditional novel mutations, 833GrA and 1114GrT, re-
spectively (fig. 2C and D). The latter mutation, found
in exon 10, introduced a nonsense codon (E422X) trun-
cating the terminal 20 amino acids. The importance that
the C-terminal has for E1-E2–subunit association was
pointed out by Ævarsson et al. (2000), who reported
that addition of a His6 tail onto E1b did not affect E1
heterotetramer assembly but did interfere with the sub-
sequent E2-association step. This observation raises the
possibility that the truncation mutant might interfere
with subunit association, although deletion of such a
large region might interfere more generally with protein
folding. The missense 833GrA mutation in exon 7 re-
sulted in the substitution G278S. This residue was also
conserved between mammalian and bacterial E1 homo-
logues, and it is situated at a hairpin turn between b-
sheet j and a-helix 9 (fig. 3B). The adjacent residue on
helix 9, W277, forms a hydrogen-bond interaction with
E231 in a hydrophobic pocket important in E1b-E1b′
interactions (Ævarsson et al. 2000). The G278S mutant
might therefore destabilize E1b-subunit interactions dur-
ing heterotetramer assembly. The severity of these mu-
tations corresponds well with the observed clinical phe-
notypes, since G278S is associated with the intermediate
phenotype and E372X is associated with the classic
phenotype.
On the basis of the mutation-analysis results, we
screened for the R183P mutation in DNA samples from
1,014 AJ individuals from the New York metropolitan
area that were obtained with informed consent. All per-
sonal identifiers were removed, and the samples were
tested anonymously. PCR amplification was performed
with genomic DNA in a volume of 50 ml containing 10
pmol of exon 5–specific primers (table 1), with 100 mM
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Figure 2 Results of mutation analysis of AJ patients with MSUD. A, C, and D, Changes (arrows) from expected wild-type sequence,
which is shown below the traces. The affected codon is boxed, and the predicted amino acid change is indicated below the codon. The different
sequence traces correspond to exon 5 in individual 4 (A), to exon 10 in individual 2 (C), and to exon 7 in individual 1 (D). B, Representative
digestion of exon 5 amplimers with NlaIV (New England Biolabs). The sizes of 100-bp-ladder marker fragments (lane M) are indicated to the
left of the gel. The samples shown were amplified from the genomic DNA of individuals 1 (lane 1), 5 (lane 2), 6 (lane 3), 7 (lane 4), and 9
(lane 5). Undigested amplimers are 237 bp in length, whereas digested products are predicted to be 99 bp and 128 bp in length.
of each dNTP (Roche Molecular Biochemicals), 5 U Taq
DNA Polymerase (Roche), 10 mM Tris-HCl, 50 mM
KCl, 0.1% Triton X-100, and 1.5 mM MgCl2. Aliquots
(4 ml) of the PCR products were blotted onto replicate
8#12-cm Hybond-N membranes (Amersham Phar-
macia Biotech), by a Biomek 2000 automated pipetting
workstation (Beckman Coulter), for hybridization with
allele-specific oligonucleotides (ASOs) for the R183P
mutation (5′-TCACTATCCCGTCCCCTT-3′) and the
wild-type sequence (5′-TCACTATCCGGTCCCCTT-3′).
Mutation detection was performed by radioactive meth-
ods as described elsewhere (Fodor et al. 1998). For ra-
dioactive detection, the membranes were hybridized for
2 h at 42C, with ∼106 cpm [32P]-ATP end-labeled probe/
ml and 10-fold molar excess of the mutant or wild-type
competitor oligonucleotide. The membranes were then
washed sequentially in 5 # SSC for 5 min at room
temperature and in 5# SSC for 5 min at 45C, followed
by a wash in 0.1 # SSC/0.1% SDS for 5 min at 45C,
and then were exposed to autoradiography.Nine carriers
were identified, which corresponded to a carrier fre-
quency of ∼1/113. Samples giving a positive signal with
the mutant ASO were reamplified, and carrier status
confirmed by the NlaIV PCR-RFLP assay.
The AJ R183P allele, which accounts for 10 of 12
mutant E1b alleles in our limited series, was present at
a frequency significantly higher than the estimated
MSUD-carrier frequency (∼1/215) in the general pop-
ulation (Peinemann et al. 1993; Danner and Doering
1998; Chuang and Shih 2000) This finding is consistent
with our observation of a disproportionate number of
AJ cases of MSUD. The expected disease incidence for
R183P homozygotes is 1/51,000. Additional compound-
heterozygous cases are expected, but the degree of allelic
heterogeneity in the population remains to be elucidated.
A rough estimate of the number of AJ individuals born
after the initiation (in 1968) of New York State newborn
screening for MSUD was derived on the basis of infor-
mation from the most recent (i.e., 1991) available United
Jewish Appeal Federation Population Estimates and the
2000 U.S. census (U.S. Census Bureau, American Fact
Finder). Assuming that the proportion of AJ individuals
!30 years of age is the same as that in the general pop-
ulation and that the percentage of AJ families has re-
mained constant, we estimated that ∼480,000 AJ indi-
viduals were born after the initiation of screening. The
expected total of approximately nine homozygous cases
is somewhat greater than our clinical observations but
within reason, considering the crudeness of the estimate.
The high prevalence of R183P in our patients sug-
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Figure 3 Ribbon representations of portions of E1b crystal struc-
ture, showing positions of mutated residues. The E1 crystal-structure
data were obtained from the NCBI Structure (Molecular Modeling
Database). Swissprot-Pdb Viewer was used to generate models and
image files. A, Ribbon diagram of b-sheets d, e, and g, with the side
chains of E146, R183, and E239, respectively, which are shown in
white. The mutated residue, R183, is indicated by the arrow, side-
chain hydrogen-bond interactions are indicated by dashed lines, and
the coordinated K ion is labeled directly. For clarity of presentation,
main-chain hydrogen interactions have been omitted. B, Overview of
entire molecule, except for structures overlying the sheet containing
R183. The residues altered by missense mutations, R183 and G228,
are indicated by bent and dashed arrows, respectively, and their side
chains are shown in white. The a-carbon backbone of residues trun-
cated by the nonsense mutation E372X are shown in white.
gests that the identification of this mutationwill facilitate
prenatal diagnosis of affected families and may permit
carrier screening after the identification of additional
common mutations in the AJ population. Population
screening is currently being offered for other diseases
with similar allele frequencies as R183P, including
Bloom syndrome (1/107) (Li et al. 1998), mucolipidosis
type IV (1/100) (Bargal et al. 2001), Niemann-Pick type
A (∼1/90) (Schuchman andMiranda 1997), and Fanconi
anemia group C (1/89) (Verlander et al. 1995; Auerbach
1997). Effective carrier detection may decrease the in-
cidence and/or the morbidity associated with delayed
diagnosis of this disorder in the AJ population.
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